<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860873</url>
  </required_header>
  <id_info>
    <org_study_id>CGSEMS1108</org_study_id>
    <nct_id>NCT00860873</nct_id>
  </id_info>
  <brief_title>Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis</brief_title>
  <official_title>Randomized Study of Two Dosage Forms (Oral Powder and Capsule) of &quot;Chondroitin + Glucosamine Sulfate&quot; Produced by the Laboratory EMS When Compared to the Product Condroflex (Oral Powder and Capsules) Produced by Laboratory Zodiac in the Treatment of Osteoarthrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study objective is to check the non-inferiority of the 2 formulations produced by EMS
      when compared with the same substances and pharmaceuticals forms of the product Condroflex
      (Zodiac), by promoting the relief of osteoarthrosis symptoms such as pain, stiffness and
      functional capacity that will be periodically measured by using the &quot;Visual Analog Scale&quot; of
      pain (VAS) and the questionnaire of Lequesne.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in pain.</measure>
    <time_frame>V0 (Screening); V1 (Inclusion); V2 (2 weeks); V3 (4 weeks); V4 (8 weeks); V5 (12 weeks); V6 (24 weeks).</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Osteoarthrosis</condition>
  <arm_group>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Powder EMS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hard Capsules EMS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Powder Zodiac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hard capsules - Zodiac</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)</intervention_name>
    <description>Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg</description>
    <arm_group_label>Test 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)</intervention_name>
    <description>Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg</description>
    <arm_group_label>Test 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)</intervention_name>
    <description>Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg</description>
    <arm_group_label>Comparator 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)</intervention_name>
    <description>Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg</description>
    <arm_group_label>Comparator 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who agree with all aspects of the study and sign the Informed Consent;

          -  Patients of both sexes;

          -  Age above 30 years;

          -  Clinical and radiological diagnosis of osteoarthritis;

          -  Osteoarthritis in grades 1-2;

          -  Patients who are conducting medical treatment and that, for trial of Investigator, is
             eligible for the study.

        Exclusion Criteria:

          -  Patients with a history of trauma clinically significant;

          -  Patients who underwent surgery on joints affected;

          -  Coexistence of diseases that might impede the successful conclusion of the trial
             (rheumatism and others);

          -  Pregnant patients and / or breastfeeding;

          -  Patients with phenylketonuria;

          -  Patients with clinical diagnosis of severe renal failure;

          -  Patients with clinical diagnosis of severe liver disease;

          -  Patients with clinical diagnosis of clotting disorders;

          -  Patients who are being treated with anti-aggregating and / or anticoagulants;

          -  Patients with sensitive components of the formula;

          -  Patients with emotional disorders that interfere with the capture of data;

          -  Patients who do not agree with the purposes of the study and did not sign the Informed
             Consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lal Clinica Pesquisa E Desenvolvimento Ltda</name>
      <address>
        <city>Valinhos</city>
        <state>Sao Paulo</state>
        <zip>13270000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <last_update_submitted>February 22, 2013</last_update_submitted>
  <last_update_submitted_qc>February 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2013</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Frederico</name_title>
    <organization>LAL Clinica</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

